Euthymics expands series A financing to work on 'next generation Straterra' - United Kingdom

Euthymics Bioscience has added $4 million to its series A financing to fund preclinical development of its second product candidate, EB-1020, a non-stimulant for adult attention deficit hyperactivity disorder (ADHD). The product is "a.....